These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15100647)

  • 1. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
    Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
    Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
    J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
    Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
    Fu X; Tao L; Cai R; Prigge J; Zhang X
    Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
    Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
    Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
    Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
    Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
    Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
    Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice.
    Takakuwa H; Goshima F; Nozawa N; Yoshikawa T; Kimata H; Nakao A; Nawa A; Kurata T; Sata T; Nishiyama Y
    Arch Virol; 2003 Apr; 148(4):813-25. PubMed ID: 12664303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
    Wong RJ; Chan MK; Yu Z; Ghossein RA; Ngai I; Adusumilli PS; Stiles BM; Shah JP; Singh B; Fong Y
    Clin Cancer Res; 2004 Jul; 10(13):4509-16. PubMed ID: 15240543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.